INAB
IN8bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.20
+3.45%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +17.6%
- EBIT
- +21.1%
- EPS
- -21.3%
- Free cash flow
- +15.2%
- Operating cash flow
- +16.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +76.6%
- EPS
- +29.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- +37.1%
- EBIT
- +34.7%
- Net income
- +36.1%
- EPS
- +74.0%
- Free cash flow
- +47.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026